To evaluate the effects of tocilizumab in primary cells from MDS patients, we purified a bone marrow CD34+ blast population that contained hematopoietic stem and progenitor cells from 4 patients with high-risk MDS. Here, CD34 is linked to myelodysplastic syndrome.